{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:35:49Z","timestamp":1762608949622,"version":"3.41.2"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV002431"],"award-info":[{"award-number":["INV002431"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Despite reinvigorated efforts in Tuberculosis (TB) drug discovery over the past 20 years, relatively few new drugs and candidates have emerged with clear utility against drug resistant TB. Over the same period, significant technological advances and learnings around target value have taken place. This has offered opportunities to re-assess the potential for optimization of previously discovered chemical matter against <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (M.tb) and for reconsideration of clinically validated targets encumbered by drug resistance. A re-assessment of discarded compounds and programs from the \u201cgolden age of antibiotics\u201d has yielded new scaffolds and targets against TB and uncovered classes, for example beta-lactams, with previously unappreciated utility for TB. Leveraging validated classes and targets has also met with success: booster technologies and efforts to thwart efflux have improved the potential of ethionamide and spectinomycin classes. Multiple programs to rescue high value targets while avoiding cross-resistance are making progress. These attempts to make the most of known classes, drugs and targets complement efforts to discover new chemical matter against novel targets, enhancing the chances of success of discovering effective novel regimens against drug-resistant TB.<\/jats:p>","DOI":"10.3389\/fcimb.2022.1029044","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T13:16:10Z","timestamp":1665062170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["\u201cUpcycling\u201d known molecules and targets for drug-resistant TB"],"prefix":"10.3389","volume":"12","author":[{"given":"Christine","family":"Roubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M","family":"Upton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.chembiol.2012.05.020","article-title":"Pathway-selective sensitization of mycobacterium tuberculosis for target-based whole-cell screening","volume":"19","author":"Abrahams","year":"2012","journal-title":"Chem. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/iub.1862","article-title":"Mycobacterium tuberculosis reporter strains as tools for drug discovery and development","volume":"70","author":"Abramovitch","year":"2018","journal-title":"IUBMB Life."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/17512433.2017.1366311","article-title":"Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis","volume":"10","author":"Alfarisi","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176088","article-title":"Design, synthesis and structure-activity relationship study of wollamide b; a new potential anti TB agent","volume":"12","author":"Asfaw","year":"2017","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.bmcl.2018.07.021","article-title":"An efficient synthetic route for preparation of antimycobacterial wollamides and evaluation of their in vitro and in vivo efficacy","volume":"28","author":"Asfaw","year":"2018","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau8959","article-title":"Opposing reactions in coenzyme a metabolism sensitize mycobacterium tuberculosis to enzyme inhibition","volume":"363","author":"Ballinger","year":"2019","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/app10165704","article-title":"Two decades of TB drug discovery efforts\u2013what have we learned","volume":"10","author":"Bandodkar","year":"2020","journal-title":"Appl. Sci."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02192-21","article-title":"Spiropyrimidinetriones: a class of DNA gyrase inhibitors with activity against mycobacterium tuberculosis and without cross-resistance to fluoroquinolones","volume":"66","author":"Basarab","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","first-page":"661","article-title":"Actinospectacin, a new antibiotic. IV. isolation, purification, and chemical properties","volume":"11","author":"Bergy","year":"1961","journal-title":"Antibiot Chemother (Northfield)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2016.01.019","article-title":"Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of mycobacterium tuberculosis complex","volume":"85","author":"Berrada","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/aac.03913-14","article-title":"Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs","volume":"59","author":"Blanco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1126\/science.aag1006","article-title":"Reversion of antibiotic resistance in mycobacterium tuberculosis by spiroisoxazoline SMARt-420","volume":"355","author":"Blondiaux","year":"2017","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1021\/acsinfecdis.6b00075","article-title":"A target-based whole cell screen approach to identify potential inhibitors of mycobacterium tuberculosis signal peptidase","volume":"2","author":"Bonnett","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1016\/j.cell.2021.06.033","article-title":"Genome-wide gene expression tuning reveals diverse vulnerabilities of m. tuberculosis","volume":"184","author":"Bosch","year":"2021","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0840-5","article-title":"Structures of an RNA polymerase promoter melting intermediate elucidate DNA unwinding","volume":"565","author":"Boyaci","year":"2019","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34823","article-title":"Fidaxomicin jams mycobacterium tuberculosis RNA polymerase motions needed for initiation via RbpA contacts","volume":"7","author":"Boyaci","year":"2018","journal-title":"Elife"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5:13985","DOI":"10.1038\/srep13985","article-title":"In vitro and In vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics","volume":"5","author":"Bruhn","year":"2015","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1096\/fba.2020-00022","article-title":"Development of a novel secondary phenotypic screen to identify hits within the mycobacterial protein synthesis pipeline","volume":"2","author":"Burke","year":"2020","journal-title":"FASEB Bioadv."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01991-21","article-title":"Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: Despite progress, more action is needed","volume":"66","author":"Butler","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1039\/c39720000660","article-title":"The crystal structure of viomycin, a tuberculostatic antibiotic","author":"Bycroft","year":"1972","journal-title":"Chem. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1021\/ja00722a043","article-title":"The 9-fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group","volume":"92","author":"Carpino","year":"1970","journal-title":"J. Am. Chem. Soc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021147","article-title":"Tuberculosis drug development: History and evolution of the mechanism-based paradigm","volume":"5","author":"Chakraborty","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1021\/acsinfecdis.1c00643","article-title":"DNA-Dependent binding of nargenicin to DnaE1 inhibits replication in mycobacterium tuberculosis","volume":"8","author":"Chengalroyen","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41588-017-0029-0","article-title":"Genome-wide analysis of multi- and extensively drug-resistant mycobacterium tuberculosis","volume":"50","author":"Coll","year":"2018","journal-title":"Nat. Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"27","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1021\/bi902097j","article-title":"Structural characterization of the mycobacterium tuberculosis biotin biosynthesis enzymes 7,8-diaminopelargonic acid synthase and dethiobiotin synthetase","volume":"49","author":"Dey","year":"2010","journal-title":"Biochemistry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMc1513236","article-title":"\u03b2-lactams against tuberculosis\u2013new trick for an old dog","volume":"375","author":"Diacon","year":"2016","journal-title":"N Engl. J. Med."},{"key":"B30","first-page":"17","volume-title":"Boosting pretomanid potency: towards reversion of resistance, mycodays","author":"Djaout","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1164\/rccm.201910-1960OC","article-title":"Early bactericidal activity of different isoniazid doses for drug-resistant tuberculosis (INHindsight): A randomized, open-label clinical trial","volume":"201","author":"Dooley","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tube.2017.01.005","article-title":"Machine learning and docking models for mycobacterium tuberculosis topoisomerase I","volume":"103","author":"Ekins","year":"2017","journal-title":"Tuberculosis (Edinb)."},{"key":"B33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.mib.2018.02.006","article-title":"Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents","volume":"45","author":"Evans","year":"2018","journal-title":"Curr. Opin. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1128\/AAC.49.4.1447-1454.2005","article-title":"In vitro and in vivo activities of macrolide derivatives against mycobacterium tuberculosis","volume":"49","author":"Falzari","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6464","DOI":"10.1073\/pnas.1718003115","article-title":"Small RNA profiling in mycobacterium tuberculosis identifies MrsI as necessary for an anticipatory iron sparing response","volume":"115","author":"Gerrick","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1021\/acsinfecdis.8b00035","article-title":"Mechanism of action of mycobacterium tuberculosis gyrase inhibitors: A novel class of gyrase poisons","volume":"4","author":"Gibson","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1021\/acsinfecdis.1c00570","article-title":"Identification of \u03b2-lactams active against mycobacterium tuberculosis by a consortium of pharmaceutical companies and academic institutions","volume":"8","author":"Gold","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1021\/acsinfecdis.1c00213","article-title":"Preclinical evaluation of inhalational spectinamide-1599 therapy against tuberculosis","volume":"7","author":"Gonzalez-Juarrero","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1021\/acs.jmedchem.2c00266","article-title":"Spiropyrimidinetrione DNA gyrase inhibitors with potent and selective antituberculosis activity","volume":"65","author":"Govender","year":"2022","journal-title":"J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1002\/anie.200900338","article-title":"Lost in transcription\u2013inhibition of RNA polymerase","volume":"48","author":"Haebich","year":"2009","journal-title":"Angew Chem. Int. Ed Engl."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00864-21","article-title":"Kanglemycin a can overcome rifamycin resistance caused by ADP-ribosylation by arr protein","volume":"65","author":"Harbottle","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","first-page":"262","volume-title":"Advances in research, production and clinical use: Proceedings of the congress on antibiotics held in Prague","author":"H\u00e9nazet","year":"1966"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/004982597240280","article-title":"Sanfetrinem and sanfetrinem-cilexetil: disposition in rat and dog","volume":"27","author":"Iavarone","year":"1997","journal-title":"Xenobiotica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2174\/1567201819666220511120215","article-title":"Intracellular activity of poly (DL-lactide-co-glycolide) nanoparticles encapsulated with prothionamide, pyrazinamide, levofloxacin, linezolid or ethambutol on multidrug-resistant mycobacterium tuberculosis","author":"Jiang","year":"2022","journal-title":"Curr. Drug Delivery"},{"key":"B46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41586-019-1315-z","article-title":"Large-Scale chemical-genetics yields new m. tuberculosis inhibitor classes","volume":"571","author":"Johnson","year":"2019","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.bmcl.2013.12.080","article-title":"Thiazolopyridone ureas as DNA gyrase b inhibitors: optimization of antitubercular activity and efficacy","volume":"24","author":"Kale","year":"2014","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B48","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1073\/pnas.37.9.570","article-title":"Antibiotic substances from basidiomycetes: VIII. pleurotus multilus (Fr.) sacc. and pleurotus passeckerianus pilat","volume":"37","author":"Kavanagh","year":"1951","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1038\/s41467-020-17734-z","article-title":"Mechanisms of drug interactions between translation-inhibiting antibiotics","volume":"11","author":"Kav\u010di\u010d","year":"2020","journal-title":"Nat. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e01773","DOI":"10.1128\/AAC.01773-18","article-title":"Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular mycobacterium tuberculosis","volume":"63","author":"Khalil","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1021\/ol502472c","article-title":"Wollamides: antimycobacterial cyclic hexapeptides from an Australian soil streptomyces","volume":"16","author":"Khalil","year":"2014","journal-title":"Org Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"8894","DOI":"10.1002\/chem.201901640","article-title":"Synthesis of new cyclomarin derivatives and their biological evaluation towards mycobacterium tuberculosis and plasmodium falciparum","volume":"25","author":"Kiefer","year":"2019","journal-title":"Chemistry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1399-3011.2005.00214.x","article-title":"100 years of peptide synthesis : ligation methods for peptide and protein synthesis with applications to beta-peptide assemblies","volume":"65","author":"Kimmerlin","year":"2005","journal-title":"J. Pept. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.aaa4690","article-title":"Antibiotics. targeting DnaN for tuberculosis therapy using novel griselimycins","volume":"348","author":"Kling","year":"2015","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201632119","article-title":"Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy","volume":"119","author":"Koh","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/jac\/dkn269","article-title":"Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of mycobacterium tuberculosis","volume":"62","author":"Kurabachew","year":"2008","journal-title":"J. Antimicrobial Chemother."},{"key":"B57","first-page":"F","article-title":"Anti-tuberculosis in vitro and in vivo activity of a new sequanamycin-like macrolide","author":"Lair","year":"2015","journal-title":"Interscience Conf. Antimicrobial Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nm.3458","article-title":"Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux","volume":"20","author":"Lee","year":"2014","journal-title":"Nat. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0922-4106(93)90104-h","article-title":"Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity","volume":"245","author":"Lemaire","year":"1993","journal-title":"Eur J Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1016\/j.bmc.2018.07.034","article-title":"An antimycobacterial pleuromutilin analogue effective against dormant bacilli","volume":"26","author":"Lemieux","year":"2018","journal-title":"Bioorg Med. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrd3975","article-title":"Platforms for antibiotic discovery","volume":"12","author":"Lewis","year":"2013","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B62","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a potent and specific m. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"30423","DOI":"10.1073\/pnas.2013706117","article-title":"The antibiotic sorangicin a inhibits promoter DNA unwinding in a mycobacterium tuberculosis rifampicin-resistant RNA polymerase","volume":"117","author":"Lilic","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molcel.2017.03.001","article-title":"Structural basis of mycobacterium tuberculosis transcription and transcription inhibition","volume":"66","author":"Lin","year":"2017","journal-title":"Mol. Cell."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase b is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tube.2017.12.002","article-title":"Trends in the discovery of new drugs for mycobacterium tuberculosis therapy with a glance at resistance","volume":"109","author":"Lohrasbi","year":"2018","journal-title":"Tuberculosis (Edinb)."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.cell.2017.05.042","article-title":"Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase","volume":"169","author":"Maffioli","year":"2017","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41564-020-00810-x","article-title":"Transcriptional regulator-induced phenotype screen reveals drug potentiators in mycobacterium tuberculosis","volume":"6","author":"Ma","year":"2021","journal-title":"Nat. Microbiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1111\/j.1742-4658.2006.05479.x","article-title":"7,8-diaminoperlargonic acid aminotransferase from mycobacterium tuberculosis, a potential therapeutic target. characterization and inhibition studies","volume":"273","author":"Mann","year":"2006","journal-title":"FEBS J."},{"key":"B70","first-page":"118","article-title":"Actinospectacin, a new antibiotic. i. discovery and biological properties","volume":"11","author":"Mason","year":"1961","journal-title":"Antibiot. Chemother. (Northfield)."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10080908","article-title":"Antituberculosis targeted drug delivery as a potential future treatment approach","volume":"10","author":"Mazlan","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/bioinformatics\/bts641","article-title":"MycPermCheck: the mycobacterium tuberculosis permeability prediction tool for small molecules","volume":"29","author":"Merget","year":"2013","journal-title":"Bioinformatics"},{"key":"B73","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1021\/ja00897a025","article-title":"Solid phase peptide synthesis. i. the synthesis of a tetrapeptide","volume":"85","author":"Merrifield","year":"1963","journal-title":"J. Am. Chem. Soc"},{"key":"B74","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1021\/np960709c","article-title":"Inhibition of bacterial RNA polymerases. peptide metabolites from the cultures of streptomyces sp","volume":"60","author":"Miao","year":"1997","journal-title":"J. Nat. Prod"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1701354","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in mycobacterium tuberculosis","volume":"50","author":"Miotto","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs mediate targeted protein degradation in bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molcel.2018.08.028","article-title":"An ansamycin natural product that is active against rifampicin-resistant mycobacterium tuberculosis","volume":"72","author":"Mosaei","year":"2018","journal-title":"Mol. Cell."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1128\/AAC.01178-16","article-title":"Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery","volume":"60","author":"Naran","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B79","first-page":"301","article-title":"Action antituberculeuse exp\u00e9rimentale d\u2019une nouvelle substance antibiotique: Le 11.072 R.P","volume":"29","author":"Noufflard-Guy-Lo\u00e9","year":"1965","journal-title":"Rev. Tuberc. Pneumol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00132-22","article-title":"GSK2556286 is a novel antitubercular drug candidate effective In vivo with the potential to shorten tuberculosis treatment","volume":"66","author":"Nuermberger","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7164\/antibiotics.27.656","article-title":"Studies on a new amino acid antibiotic, amiclenomycin","volume":"27","author":"Okami","year":"1974","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040323","article-title":"Antimicrobial peptides as potential anti-tubercular leads: A concise review","volume":"14","author":"Oliveira","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1021\/acsinfecdis.1c00261","article-title":"Synthetic peptide derived from scorpion venom displays minimal toxicity and anti-infective activity in an animal model","volume":"7","author":"Oliveira","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1021\/acsinfecdis.0c00223","article-title":"A semisynthetic kanglemycin shows In vivo efficacy against high-burden rifampicin resistant pathogens","volume":"6","author":"Peek","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/17475198211047801","article-title":"Antitubercular and antibacterial activities of isoxazolines derived from natural products: Isoxazolines as inhibitors of mycobacterium tuberculosis InhA","volume":"45","author":"Phanumartwiwath","year":"2021","journal-title":"J. Chem. Res."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105242","article-title":"Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery","volume":"115","author":"Prasad","year":"2021","journal-title":"Bioorg Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ejmech.2019.02.023","article-title":"A fragment-based approach towards the discovery of n-substituted tropinones as inhibitors of mycobacterium tuberculosis transcriptional regulator EthR2","volume":"167","author":"Prevet","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1021\/acschembio.1c00131","article-title":"Mycobacterium tuberculosis PanD structure-function analysis and identification of a potent pyrazinoic acid-derived enzyme inhibitor","volume":"16","author":"Ragunathan","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"B89","first-page":"S591","article-title":"Thompson And David barros. sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis","author":"Ram\u00f3n- Garc\u00eda","year":"2019"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2017.00075","article-title":"Targeting DNA replication and repair for the development of novel therapeutics against tuberculosis","volume":"4","author":"Reiche","year":"2017","journal-title":"Front. Mol. Biosci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"11273","DOI":"10.1021\/ja992482o","article-title":"Cyclomarins a\u2013c, new antiinflammatory cyclic peptides produced by a marine bacterium (Streptomyces sp.)","volume":"121","author":"Renner","year":"1999","journal-title":"J. Am. Chem. Soc."},{"key":"B92","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.drudis.2016.09.009","article-title":"A new \u2018golden age\u2019 for the antitubercular target InhA","volume":"22","author":"Ro\u017eman","year":"2017","journal-title":"Drug Discovery Today"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/toxins6031002","article-title":"Multiple toxin-antitoxin systems in mycobacterium tuberculosis","volume":"6","author":"Sala","year":"2014","journal-title":"Toxins (Basel)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"915","DOI":"10.4155\/tde.13.62","article-title":"Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis","volume":"4","author":"Salomon","year":"2013","journal-title":"Ther. Deliv."},{"key":"B95","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1128\/AAC.00288-16","article-title":"Small-molecule inhibitors targeting topoisomerase I as novel antituberculosis agents","volume":"60","author":"Sandhaus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B96","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1021\/acsinfecdis.6b00051","article-title":"Prediction of drug penetration in tuberculosis lesions","volume":"2","author":"Sarathy","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1002\/anie.201101740","article-title":"The natural product cyclomarin kills mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease","volume":"50","author":"Schmitt","year":"2011","journal-title":"Angew Chem. Int. Ed Engl."},{"key":"B98","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl. Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1021\/acs.accounts.0c00878","article-title":"Strategies to combat multi-drug resistance in tuberculosis","volume":"54","author":"Singh","year":"2021","journal-title":"Acc Chem. Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1128\/AAC.40.9.2142","article-title":"In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms","volume":"40","author":"Singh","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3109\/10717544.2015.1074765","article-title":"Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review","volume":"23","author":"Singh","year":"2016","journal-title":"Drug Deliv."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74419","article-title":"Host-pathogen genetic interactions underlie tuberculosis susceptibility in genetically diverse mice","volume":"11","author":"Smith","year":"2022","journal-title":"Elife"},{"key":"B103","doi-asserted-by":"publisher","first-page":"18744","DOI":"10.1073\/pnas.2002738117","article-title":"Morphological profiling of tubercle bacilli identifies drug pathways of action","volume":"117","author":"Smith","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B104","doi-asserted-by":"publisher","first-page":"21309","DOI":"10.1038\/s41598-020-78269-3","article-title":"High-throughput screening to discover inhibitors of the CarD\u00b7RNA polymerase protein-protein interaction in mycobacterium tuberculosis","volume":"10","author":"Stefan","year":"2020","journal-title":"Sci. Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.1016\/j.bmcl.2007.09.048","article-title":"Discovery of novel isoxazolines as anti-tuberculosis agents","volume":"17","author":"Tangallapally","year":"2007","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B106","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/0769-2609(87)90151-7","article-title":"Aspects of the antituberculous activity of 27753-RP, a new semisynthetic derivative of griselimycine","volume":"138","author":"Toyohara","year":"1987","journal-title":"Ann. Inst. Pasteur. Microbiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1021\/acsinfecdis.9b00277","article-title":"Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity","volume":"6","author":"Villemagne","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S2666-5247(21)00301-3","article-title":"The 2021 WHO catalogue of mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis","volume":"3","author":"Walker","year":"2022","journal-title":"Lancet Microbe"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1164\/rccm.202002-0264ED","article-title":"Clarity with INHindsight: High-dose isoniazid for drug-resistant tuberculosis with inhA mutations","volume":"201","author":"Wasserman","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0962-8479(92)90145-A","article-title":"In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule","volume":"73","author":"Watt","year":"1992","journal-title":"Tuber Lung Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nm.1950","article-title":"Synthetic EthR inhibitors boost antituberculous activity of ethionamide","volume":"15","author":"Willand","year":"2009","journal-title":"Nat. Med."},{"key":"B112","unstructured":""},{"key":"B113","unstructured":"World Health OrganizationTarget regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicin resistant and pan-TB treatment regimens2016"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e00021","DOI":"10.1128\/AAC.00021-19","article-title":"Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B115","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4172\/2161-0444.1000293","article-title":"Investigation of cross-resistance between rifampin and rifabutin in multi-drug resistant mycobacterium tuberculosis","volume":"5","author":"Yan","year":"2015","journal-title":"Med. Chem."},{"key":"B116","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1164\/art.1951.63.1.25","article-title":"The effect of viomycin in vitro and in vivo on mycobacterium tuberculosis","volume":"63","author":"Youmans","year":"1951","journal-title":"Am. Rev. Tuberculosis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijantimicag.2013.10.010","article-title":"Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice","volume":"43","author":"Zhao","year":"2014","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1029044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T13:16:19Z","timestamp":1665062179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.1029044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":117,"alternative-id":["10.3389\/fcimb.2022.1029044"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.1029044","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"1029044"}}